A new report highlights the important work of companies across the industry in boosting access to vaccines worldwide – and warns of the challenges ahead.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has published its new code of practice, introducing a total ban on gifts and promotional items for pres
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.